Patents by Inventor Kateri A. Moore

Kateri A. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND SYSTEM OF HUMAN HEMOGENIC REPROGRAMING
    Publication number: 20200347352
    Abstract: This disclosure provides a method for programming human somatic cells into hematopoietic stem cells (HSCs). The method includes inducing expression of the 3GF reprogramming transcription factor cocktail, including GATA2, GFI1B, GFI1, and FOS transcription factors, in human somatic cells. Further, this disclosure also demonstrates co-culturing HSCs with AFT024 stroma cells results in more functional cells, both qualitatively and quantitatively.
    Type: Application
    Filed: January 25, 2019
    Publication date: November 5, 2020
    Inventors: Kateri A. Moore, Ihor R. Lemischka, Michael G. Daniel
  • Methods for programming differentiated cells into hematopoietic stem cells
    Patent number: 9540612
    Abstract: The disclosure relates to the development of methods for making hematopoietic stem cells from differentiated cells by introducing and expressing transcription factors. More particularly, the disclosure provides methods for redirecting differentiated cells to a hematopoietic stem cell state or to a hemogenic endothelial cell state by direct programming with specific combinations of transcription factors.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: January 10, 2017
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Ihor R. Lemischka, Kateri Moore, Carlos Filipe Pereira
  • METHODS FOR PROGRAMMING DIFFERENTIATED CELLS INTO HEMATOPOIETIC STEM CELLS
    Publication number: 20150004145
    Abstract: The disclosure relates to the development of methods for making hematopoietic stem cells from differentiated cells by introducing and expressing transcription factors. More particularly, the disclosure provides methods for redirecting differentiated cells to a hematopoietic stem cell state or to a hemogenic endothelial cell state by direct programming with specific combinations of transcription factors.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 1, 2015
    Inventors: Ihor R. Lemischka, Kateri Moore, Carlos Filipe Pereira
  • Use of delta-like protein to inhibit the differentiation of stem cells
    Patent number: 6613565
    Abstract: Primitive hematopoietic stem cells are closely associated with discrete in vivo microenvironments. These “niches” are thought to provide the molecular signals that mediate stem cell differentiation and self renewal. We have dissected the fetal liver microenvironment into distinct cellular components by establishing an extensive panel of stromal cell lines. One particular cell line maintains repopulating stem cells for prolonged in vitro culture periods. A subtraction cloning strategy has yielded a cDNA which encodes a cell surface glycoprotein with a restricted pattern of expression among stromal cell lines. This molecule, previously identified as dlk/Pref-1, contains EGF-like repeats which are related to those in the Notch/Delta/Serrate family of proteins. We have investigated the potential role of this molecule in hematopoietic stem/progenitor cell regulation.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: September 2, 2003
    Assignees: ImClone Systems Incorporated, Trustees of Princeton University
    Inventors: Larry Witte, Bronislaw Pytowski, Kateri A. Moore, Ihor R. Lemischka
  • Genes that regulate hematopoietic blood forming stem cells and uses thereof
    Publication number: 20020064855
    Abstract: The present invention provides an isolated nucleic acid derived from an isolated hematopoietic stem cell. The present invention additionally provides an isolated hematopoietic stem cell specific protein or a portion thereof encoded by the provided nucleic acid. In addition, the present invention provides a method for generating a stem cell/progenitor cell from a primitive hematopoietic cell. Also, the present invention farther provides a method for identifying the presence in a sample of a compound that modulates hematopoietic stem cell activity. The present invention additionally provides a molecularly defined primitive hematopoietic stem cell. Finally, the present invention provides a method of ex vivo expansion of hematopoietic stem cells.
    Type: Application
    Filed: February 21, 2001
    Publication date: May 30, 2002
    Inventors: Ihor Lemischka, Kateri Moore